Assessing hepatoprotective effects of antioxidants on amiodarone-induced cytotoxicity in human hepatoma HepaRG cell line

Filimonova KS, Rogovskaya NYu, Beltyukov PP, Babakov VN
About authors

Research Institute of Hygiene, Occupational Pathology and Human Ecology of the Federal Medical Biological Agency, Leningrad Region, Russia

Correspondence should be addressed: Vladimir Nikolaevich Babakov
Kapitolovo, 93, p/o Kuzmolovsky, Leningradskaja oblast, 188663; ur.hcepg@vokabab

Received: 2021-07-20 Accepted: 2021-08-11 Published online: 2021-09-23
  1. Ivashkin VT, Baranovsky AYu, Raikhelson KL, i dr. Lekarstvennye porazhenija pecheni (klinicheskie rekomendacii dlja vrachej). Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2019; 29 (1): 101–31. Russian.
  2. Stine JG, Lewis JH. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016; 10 (4): 517–36.
  3. Mujović N, Dobrev D, Marinković M, et al. The role of amiodarone in contemporary management of complex cardiac arrhythmias. Pharmacol Res. 2020; 151: 104521.
  4. Hashmi A, Keswani NR, Kim S, et al. Hepatic dysfunction in patients receiving intravenous amiodarone. South Med J. 2016; 109 (2): 83–6.
  5. Waldhauser KM, Török M, Ha H-R, et al. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther. 2006; 319 (3): 1413–23.
  6. Serviddio G, Bellanti F, Giudetti AM, et al. Mitochondrial oxidative stress and respiratory chain dysfunction account for liver toxicity during amiodarone but not dronedarone administration. Free Radic Biol Med. 2011; 51 (12): 2234–42.
  7. Golli-Bennour EE, Bouslimi A, Zouaoui O, et al. Cytotoxicity effects of amiodarone on cultured cells. Exp Toxicol Pathol. 2012; 64 (5): 425–30.
  8. Schumacher JD, Guo GL. Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol. 2015; 289 (1): 40–7.
  9. Grünig D, Duthaler U, Krähenbüh S. Effect of Toxicants on Fatty Acid Metabolism in HepG2 Cells. Front Pharmacol. 2018; 9: 257.
  10. Erez N, Hubel E, Avraham R, et al. Hepatic amiodarone lipotoxicity is ameliorated by genetic and pharmacological inhibition of endoplasmatic reticulum stress. Toxicol Sci. 2017; 159 (2): 402–12.
  11. Durukan AB, Erdem B, Durukan E, et al. May toxicity of amiodarone be prevented by antioxidants? A cell-culture study. J Cardiothorac Surg. 2012; 7 (1): 61.
  12. Galli F, Azzi A, Birringer M, et al. Vitamin E: Emerging aspects and new directions. Free Radic Biol Med. 2017; 102: 16–36.
  13. Chughlay MF, Kramer N, Spearman CW, et al. N‐acetylcysteine for non–paracetamol drug–induced liver injury: a systematic review. Br J Clin Pharmacol. 2016; 81: 1021–9.
  14. Anstee QM, Day CP. S-adenosylmethionine (SAMe) therapy in liver disease: A review of current evidence and clinical utility. J Hepatol. 2012; 57 (5): 1097–109.
  15. Aninat C, Piton A, Glaise D, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos. 2006; 34 (1): 75–83.
  16. Yokoyama Y, Sasaki Y, Terasaki N, et al. Comparison of drug metabolism and its related hepatotoxic effects in HepaRG, cryopreserved human hepatocytes, and HepG2 cell cultures. Biol Pharm Bull. 2018; 41 (5): 722–32.
  17. Tomida T, Okamura H, Yokoi T, et al. A modified multiparametric assay using HepaRG cells for predicting the degree of druginduced liver injury risk. J Appl Toxicol. 2017; 37 (3): 382–90.
  18. Wu Y, Geng X, Wang J, et al. The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. Cell Biol Toxicol. 2016; 32 (1): 37–59.
  19. McGovern B, Garan H, Ruskin JN. Serious adverse effects of amiodarones. Clin Cardiol. 1984; 7 (3): 131–7.
  20. Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. Drug Metab Rev. 2012; 44 (1): 34–87.
  21. Anthérieu S, Rogue A, Fromenty B, et al. Induction of vesicular steatosis by amiodarone and tetracycline is associated with upregulation of lipogenic genes in heparg cells. Hepatology. 2011; 53 (6): 1895–905.
  22. Ye H, Nelson LJ, Gómez del Moral M, et al. Dissecting the molecular pathophysiology of drug induced liver injury. World J Gastroenterol. 2018; 24 (13): 1373–85.
  23. Yuan L, Kaplowitz N. Mechanisms of drug induced liver injury. Clin Liver Dis. 2013; 17 (4): 507–18.
  24. Iorga A., Dara L. Cell death in drug-induced liver injury. Adv Pharmacol. 2019; 85: 31–74.
  25. Ali SE, Waddington JC, Park BK, et al. Definition of the Chemical and Immunological Signals Involved in Drug-Induced Liver Injury. Chem Res Toxicol. 2020; 33 (1): 61–76.
  26. Bognar Z, Fekete K, Antus C, et al. Desethylamiodarone — A metabolite of amiodarone — Induces apoptosis on T24 human bladder cancer cells via multiple pathways. PLoS One. 2017; 12 (12): e0189470.
  27. Steinberg E, Fluksman A, Zemmour C, et al. Low dose amiodarone reduces tumor growth and angiogenesis. Sci Rep. 2020; 10 (1): 18034.
  28. Abdulkhaleq F, Alhussainy T, Badr M, et al. Antioxidative stress effects of vitamins C, E, and B12, and their combination can protect the liver against acetaminophen-induced hepatotoxicity in rats. Drug Des Devel Ther. 2018; 12: 3525–33.